Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc.

FENCNYSE / NASDAQHealthcareSmall cap

$13.09-$0.36 (-2.7%)

Last close · Data as of Nov 20, 2026

Market cap
$318.2M
P/E
-32.7x
EV / EBITDA
-37.8x
Revenue
$44.6M
Net margin
-21.8%
ROCE
-10.6%

+67.0% over the last year

Fennec Pharmaceuticals Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+25.1%
3M
+15.3%
6M
+34.3%
1Y
+67.0%
5Y
Hidden
  • This period includes a one-day price step on 29 Nov 2021 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

52-week range

Day change -$0.36 (-2.7%) from $13.45 to $13.09 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in FENC, bought on each weekday since 2021.

News & filings

What Fennec Pharmaceuticals filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 9.7 million US dollars in fiscal 2025.

Strengths (1)

  • Revenue more than doubled a year on average over three years.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.

Read moreShow less

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Sector
Healthcare
Shares outstanding
34.2M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$318.2M
P/E
-32.7x
P/B
9.0x
EV / EBITDA
-37.8x
EV / Sales
6.3x
P/S
7.1x
52-week high
$13.58
52-week low
$5.77

Profitability

Operating margin
-14.2%
Net margin
-21.8%
EBITDA margin
-16.7%
ROE
-27.5%
ROCE
-10.6%
ROA
-13.8%
Asset turnover
0.63

Growth

Revenue
$44.6M
Revenue growth, 1Y
-6.1%
Revenue CAGR, 3Y
207.5%
Net profit growth, 1Y
2134.2%
Free cash flow
-$12.5M

Solvency

Current ratio
6.37
Debt / Equity
0.00
Debt / Assets
0.00
CFO / Net profit
1.28
Cash / Market cap
11.6%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$44.6M
Cost of revenue$3.8M
Gross profit$40.9M
Operating expenses$47.2M
Research and development$250.0k
Selling, general and administrative$46.9M
Operating income-$6.3M
Interest and other-$3.3M
Pretax income-$9.6M
Tax and other$100.0k
Net income-$9.7M

Revenue and net profit

Revenue fell 6.1% in FY2025; net profit is the dashed line.

Fennec Pharmaceuticals Inc. revenue and net profit by fiscal year
Fennec Pharmaceuticals Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$1.5M-$23.7M
FY2023$21.3M-$16.0M
FY2024$47.5M-$436.0k
FY2025$44.6M-$9.7M

Cash flows

FY2025: -$12.5M from operations, -$12.5M free after investment (dashed).

Fennec Pharmaceuticals Inc. operating and free cash flow by fiscal year
Fennec Pharmaceuticals Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$18.1M-$18.1M
FY2023-$17.1M-$17.1M
FY2024$27.0M$27.0M
FY2025-$12.5M-$12.5M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$44.6M-6.1%1Y
EBITDA
-$7.5M-255.3%1Y
Net profit
-$9.7M
Cash from operations
-$12.5M-146.2%1Y
Free cash flow
-$12.5M-146.2%1Y
Revenue CAGR, 3Y
207.5%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$44.6M-$7.5M-$9.7M-$12.5M-27.5%-6.1%+2134.2%

Monthly returns

Month-by-month returns of FENC across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$70.5M
Liabilities—
Non-current liabilities$24.6M
Equity$35.5M
Paid-in capital$73.7M
Retained earnings-$229.4M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; FENC highlighted.

P/E against peers

FENC has no positive P/E; the peer median is 8.6x.

Not shown (no positive earnings and no EV / Sales): Fennec Pharmaceuticals Inc., Humacyte, Inc., Rocket Pharmaceuticals, Inc., DiaMedica Therapeutics Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Fennec Pharmaceuticals Inc.FENCthis company$318.2M-32.7x9.0x-27.5%-37.8x
908 Devices Inc.MASS$333.5M17.1x2.3x13.6%-12.6x
Abeona Therapeutics Inc.ABEO$331.7M4.7x2.1x44.7%3.5x
Humacyte, Inc.HUMA$330.8M-8.1x106.4x-1313.4%-15.5x
Organogenesis Holdings Inc.ORGO$319.1M8.6x1.1x12.3%3.7x
Rocket Pharmaceuticals, Inc.RCKT$318.8M-1.4x1.2x-80.5%-1.3x
SIGA Technologies, Inc.SIGA$317.7M13.6x1.6x11.7%6.7x
DiaMedica Therapeutics Inc.DMAC$314.7M—5.6x-58.4%—
Electromed, Inc.ELMD$304.0M40.3x7.0x17.4%26.7x
Peer median—8.6x2.2x12.0%3.5x

Year-to-date ROI

FENC since 1 January, against earlier years.

Historical volatility

FENC's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Fennec Pharmaceuticals Inc. operating margin by fiscal year
Fennec Pharmaceuticals Inc. operating margin by fiscal year
DateOperating margin
FY2022-1476.6%
FY2023-61.5%
FY20245.2%
FY2025-14.2%
LineFY2025
Cost of revenueCost Of Revenue$3.8M
Gross profitGross Profit$40.9M
Operating expensesOperating Expense$47.2M
Research and developmentResearch And Development$250.0k
Depreciation and amortisationDepreciation And Amortization In Income Statement$60.0k
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$60.0k
Amortization$60.0k
Amortisation of intangiblesAmortization Of Intangibles Income Statement$60.0k
Total expensesTotal Expenses$51.0M
Pretax incomePretax Income-$9.6M

Learn while you research

Academy chapters picked for Fennec Pharmaceuticals Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →